Watch CRSP. Know when insiders buy.
One email the day a filing lands. Free.
CRSP
CRISPR Therapeutics AG
48.67
−0.72 −1.46%
USD · Oct 26, 03:01 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
38
FLAG · insiders 25, shorts 50
Insiders, 90 days
−$4.9M
net selling · 0 buys, 7 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.7BP/E —DIV YIELD —FCF YIELD -7.89%REV TTM $13.4M −64.8%NET INCOME −$451.1MNET DEBT $294.9M52W 44.34 – 65.72NEXT EARNINGS Nov 9 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $10.2M | +1041.4% | — | −$117.3M | −$91.2M | — | -0.94 | −$83.5M | $648K | −$84.1M | Aug 3 |
| Q1 2026 · Mar 31 | $1.5M | +68.6% | — | −$130.2M | −$122.9M | — | -1.28 | −$108.9M | $504K | −$109.4M | Aug 3 |
| Q4 2025 · Dec 31derived | $864K | −97.6% | — | −$154.8M | −$130.6M | — | -1.35 | −$92.6M | $517K | −$93.1M | Feb 12 |
| Q3 2025 · Sep 30 | $889K | +47.7% | — | −$132.1M | −$106.4M | — | -1.17 | −$84.6M | $74K | −$84.7M | Nov 10 |
| Q2 2025 · Jun 30 | $892K | +72.5% | — | −$229.3M | −$208.5M | — | -2.40 | −$113.9M | $117K | −$114M | Aug 3 |
| Q1 2025 · Mar 31 | $865K | +71.6% | — | −$148.4M | −$136M | — | -1.58 | −$53.9M | $206K | −$54.2M | Aug 3 |
| Q4 2024 · Dec 31derived | $35.7M | −82.3% | — | −$64.6M | −$37.3M | −141.8% | -0.42 | −$50M | $254K | −$50.3M | Feb 12 |
| Q3 2024 · Sep 30 | $602K | — | — | −$110.1M | −$85.9M | — | -1.01 | −$106.9M | $219K | −$107.1M | Nov 10 |
| Q2 2024 · Jun 30 | $517K | — | — | −$151.3M | −$126.4M | — | -1.49 | −$95.6M | $707K | −$96.3M | Nov 10 |
| Q1 2024 · Mar 31 | $504K | — | — | −$140.6M | −$116.6M | — | -1.43 | $109.8M | $721K | $109M | Nov 10 |
| Q4 2023 · Dec 31derived | $201.2M | — | — | $69.6M | $89.3M | — | 1.13 | −$96.1M | $738K | −$96.8M | Feb 12 |
| Q3 2023 · Sep 30 | $0 | — | — | −$132.4M | −$112.2M | — | -1.41 | −$39.9M | $2.1M | −$42M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $3.5M | — | −$664.6M | −$581.6M | -16569.8% | -6.47 | −$345M | $914K | −$345.9M | — | — |
| FY2024 · to Dec 31 | $37.3M | — | −$466.6M | −$366.3M | -981.5% | -4.34 | −$142.8M | $1.9M | −$144.7M | — | — |
| FY2023 · to Dec 31 | $371.2M | — | −$222.5M | −$153.6M | -41.4% | -1.94 | −$260.4M | $9.5M | −$269.8M | — | — |
| FY2022 · to Dec 31 | $1.2M | — | −$673.2M | −$650.2M | -54271.7% | -8.36 | −$495.7M | $37.2M | −$532.9M | — | — |
| FY2021 · to Dec 31 | $915M | — | $373.5M | $377.7M | 41.3% | 4.70 | $539M | $81.7M | $457.3M | — | — |
| FY2020 · to Dec 31 | $719K | — | −$354.4M | −$348.9M | -48520.9% | -5.29 | −$238.4M | $18.4M | −$256.7M | — | — |
Every number comes from CRISPR Therapeutics AG's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.